Document Detail


Posttransplant diabetes mellitus in renal allograft recipients: A prospective multicenter study at 2 years.
MedLine Citation:
PMID:  17175323     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The purpose of this study was to investigate the incidence and risk factors for the development of diabetes mellitus after kidney transplantation (PTDM). A total of 1783 nondiabetic renal allograft recipients transplanted from January 2000 to December 2002 were included. Diabetes was diagnosed following American Diabetes Association criteria. While 1276 patients were treated with tacrolimus (Tac), mycophenolate mofetil (MMF), and steroids, 507 patients received cyclosporine-ME (CsA), MMF, and steroids. PTDM incidence at 6, 12, and 24 months was 14.2%, 12.8%, and 13.3%, respectively. Cumulative incidence during the follow-up was 21.6%. Only 121 of the diabetic patients (47.6%) at 6 months remained diabetic at 24 months. Furthermore, 60 patients of 116 patients on insulin at 6 months (51.7%) remained on treatment at 24 months. The cumulative incidence of PTDM was similar in the two immunosuppressive treatments (19.7% on CsA-MMF vs 22.3% on Tac-MMF; P = NS). However, at 24 months, 14 of 50 diabetic patients on CsA-MMF (28%) and 74 of 161 patients on Tac-MMF (45.9%) were on insulin treatment (P < .05). By Cox regression analysis, age older than 60 years (RR 1.61; 95%CI 1.28-2.04; P < .001), body mass index (BMI) > 30 kg/m2 at transplantation (RR 1.66; 95%CI 1.27-2.16; P < .001), and immunosuppression with Tac (RR 1.30; 95%CI 1.02-1-66; P = .033) were associated with PTDM. In conclusions, the incidence of PTDM at 24 months in immunosuppressive protocols including MMF is about 22%, and it is associated with older age, increased BMI, and immnunosuppression with Tac.
Authors:
R Marcén; J M Morales; D del Castillo; J M Campistol; D Serón; F Valdés; F Anaya; A Andrés; M Arias; J Bustamante; L Capdevila; F Escuin; S Gil-Vernet; M Gonzalez-Molina; I Lampreave; F Oppenheimer; L Pallardó;
Related Documents :
23197113 - Improvement of insulin sensitivity promotes extravillous trophoblast cell migration sti...
11679453 - Weighing in on type 2 diabetes in the military: characteristics of u.s. military person...
6408703 - Evidence of the heterogeneity of the proliferative capacity and for the selection of va...
Publication Detail:
Type:  Journal Article; Multicenter Study    
Journal Detail:
Title:  Transplantation proceedings     Volume:  38     ISSN:  0041-1345     ISO Abbreviation:  Transplant. Proc.     Publication Date:  2006 Dec 
Date Detail:
Created Date:  2006-12-18     Completed Date:  2007-04-30     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0243532     Medline TA:  Transplant Proc     Country:  United States    
Other Details:
Languages:  eng     Pagination:  3530-2     Citation Subset:  IM    
Affiliation:
Servicio de Nefrología, Hospital Ramón y Cajal, Madrid, Spain. rmarcen.hrc@salud.madrid.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenal Cortex Hormones / therapeutic use
Adult
Body Mass Index
Diabetes Mellitus / epidemiology*
Drug Therapy, Combination
Female
Follow-Up Studies
Humans
Immunosuppressive Agents / therapeutic use
Incidence
Kidney Transplantation / adverse effects*
Male
Middle Aged
Postoperative Complications / epidemiology
Prospective Studies
Time Factors
Transplantation, Homologous
Chemical
Reg. No./Substance:
0/Adrenal Cortex Hormones; 0/Immunosuppressive Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cardiac functional and morphologic changes of renal allograft recipients in the early posttransplant...
Next Document:  Immunosuppression and cancer: A comparison of risks in recipients of organ transplants and in HIV-po...